Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

The Effect of Calcium Carbonate and Cholecalciferol on Pharmacokinetic Interaction of 99mTc-CTMP Radiopharmaceuticals for Bone Scanning in Rats (Rattus norvegicus)

Atom Indonesia · Vol. 44 No. 2 (2018) · hlm. 69–73

DOI
10.17146/aij.2018.852
ISSN
2356-5322, 0126-1568
Terbit
2018-08-21
Penerbit
National Research and Innovation Agency
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

Hypocalcemia is one of manifestation of bone metastases which could be treated using calcium carbonate and cholecalciferol. Tc-99m radiolabeled 1,4,8,11-tetraazacyclo tetradecyl-1,4,8,11-tetramethylene phosponic acid(against 99mTc-CTMP)on the other hand is a radioactive complex compound which has an affinity toward bone. Therefore, it could be used as bone tracer (radiopharmaceutical) in bone imaging.However, there has been a concern regarding the use 99mTc-CTMPon patients who have been treated with calcium carbonate and cholecalciferol. In this circumstance 99mTc-CTMPcould interact withcalcium carbonate and cholecalciferol and it might then interefere with the imaging results. Therefore, the aim of this study was to determine the pharmacokinetic behavior of 99mTc-CTMP in rats (Rattus norvegicus)that had been previously treated with calcium carbonate and cholecalciferol. The pharmacokineticstudies were performed using four groups of animal modeland each groups consists of three rats. The groups were classified as control (I), rats treated with calcium carbonate (II), rats treated with cholecalciferol (III), and rats treated with both calcium carbonate and cholecalciferol (IV). After the rats were treated for 3 days,99mTc-CTMP radiopharmaceutical was injected through a tail vein of each rat. At specific time intervals after 99mTc-CTMP administration, blood wasthen extracted from the tail, weighedand counted using a single channel analyzer. The percentage of radioactivity in blood at a certain interval wasthen calculated to determine the distribution half-time and the elimination half-time. Thedistribution half-time of group I, II, II, and IV were 0.43+0.13, 0.25+0.18, 0.32+0.10, and 0.47+0.07 hours, respectively, while the elimination half-time were 2.56+0.18, 4.48+0.56, 4.47+1.13, 6.19+1.97 respectively. The results of T-test showed that there was no significant difference of distribution half-time between the three treated groups and the control group. However, there was significant difference of elimination half-time between the three treatment groups and control. This research showed that giving calcium carbonate or, cholecalciferol, and both for 3 days prior administration of 99mTc-CTMP would mantain elimination half-time which resulted in longer excretion/ elimination time.

Kata kunci

Jaringan kolaborasi para penulis

26 penulis · 75 tautan kepenulisan bersama · 39 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • National Nuclear Energy Agency of Indonesia
  • Universitas Bakti Tunas Husada
  • Universitas Jenderal Achmad Yani
  • Sekolah Tinggi Farmasi Indonesia
  • Bandung Institute of Technology
  • Nuclear Energy Agency
  • Padjadjaran University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Maula Eka SriyaniNational Nuclear Energy Agency of Indonesia3
Eva Maria WidyasariNational Nuclear Energy Agency of Indonesia2
Iim HalimahNational Nuclear Energy Agency of Indonesia2
S. R. PajrinSekolah Tinggi Farmasi Indonesia2
Teguh Hafiz Ambar WibawaNational Nuclear Energy Agency of Indonesia1
A. HanafiahSekolah Tinggi Farmasi Indonesia1
Nanny Kartini OekarNational Nuclear Energy Agency of Indonesia1
Nurlaila ZainuddinNational Nuclear Energy Agency of Indonesia1
Z NurlailaNational Nuclear Energy Agency of Indonesia1
Heni RachmawatiBandung Institute of Technology1
Aang Hanafiah WangsaatmadjaNational Nuclear Energy Agency of Indonesia1
DEBBIE SOEFIE RETNONINGRUMBandung Institute of Technology1
Veronika Yulianti SusiloNational Nuclear Energy Agency of Indonesia1
Ruswanto RuswantoUniversitas Bakti Tunas Husada1
Anindita Tri Kusuma PratitaUniversitas Bakti Tunas Husada1
Febby PratamaUniversitas Bakti Tunas Husada1
Tita NofiantiUniversitas Bakti Tunas Husada1
Holis Abdul HolikPadjadjaran University1
Rizky Juwita SugihartiNational Nuclear Energy Agency of Indonesia1
Dian Ayu UtamiUniversitas Jenderal Achmad Yani1
Mega Susilo DwikeUniversitas Jenderal Achmad Yani1
Muharram MarzukiUniversitas Jenderal Achmad Yani1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://atomindonesia.brin.go.id/index.php/aij/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Effect of Calcium Carbonate and Cholecalciferol on Pharmacokinetic Interaction of 99mTc-CTMP Radiopharmaceuticals for Bone Scanning in Rats (Rattus norvegicus)</dc:title>
	<dc:creator>Mahendra, I.</dc:creator>
	<dc:creator>Daruwati, I.</dc:creator>
	<dc:creator>Ambarwibawa, T. H.</dc:creator>
	<dc:creator>Nuraeni, W.</dc:creator>
	<dc:subject xml:lang="en-US">99mTc-CTMP; Calcium carbonate; Cholecalciferol; Pharmacokinetics interaction</dc:subject>
	<dc:description xml:lang="en-US">Hypocalcemia is one of manifestation of bone metastases which could be treated  using calcium carbonate and cholecalciferol. Tc-99m radiolabeled 1,4,8,11-tetraazacyclo tetradecyl-1,4,8,11-tetramethylene phosponic acid(against 99mTc-CTMP)on the other hand is a radioactive complex compound which has an affinity toward bone. Therefore, it could be used as bone tracer (radiopharmaceutical) in bone imaging.However, there has been a concern regarding the use 99mTc-CTMPon patients who have been treated with calcium carbonate and cholecalciferol. In this circumstance 99mTc-CTMPcould interact withcalcium carbonate and cholecalciferol and it might then interefere with the imaging results. Therefore, the aim of this study was to determine the pharmacokinetic behavior of 99mTc-CTMP in rats (Rattus norvegicus)that had been previously treated with calcium carbonate and cholecalciferol. The pharmacokineticstudies were performed using four groups of animal modeland each groups consists of three rats. The groups were classified as control (I), rats treated with calcium carbonate (II), rats treated with cholecalciferol (III), and rats treated with both calcium carbonate and cholecalciferol (IV). After the rats were treated for 3 days,99mTc-CTMP radiopharmaceutical was injected through a tail vein of each rat. At specific time intervals after 99mTc-CTMP administration, blood wasthen extracted from the tail, weighedand counted using a single channel analyzer. The percentage of radioactivity in blood at a certain interval wasthen calculated to determine the distribution half-time and the elimination half-time. Thedistribution half-time of group I, II, II, and IV were 0.43+0.13, 0.25+0.18, 0.32+0.10, and 0.47+0.07 hours, respectively, while the elimination half-time were 2.56+0.18, 4.48+0.56, 4.47+1.13, 6.19+1.97 respectively. The results of T-test showed that there was no significant difference of distribution half-time between the three treated groups and the control group. However, there was significant difference of elimination half-time between the three treatment groups and control. This research showed that giving calcium carbonate or, cholecalciferol, and both for 3 days prior administration of 99mTc-CTMP would mantain elimination half-time which resulted in longer excretion/ elimination time.</dc:description>
	<dc:publisher xml:lang="en-US">National Research and Innovation Agency</dc:publisher>
	<dc:contributor xml:lang="en-US">BATAN</dc:contributor>
	<dc:date>2018-08-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://atomindonesia.brin.go.id/index.php/aij/article/view/852</dc:identifier>
	<dc:identifier>10.17146/aij.2018.852</dc:identifier>
	<dc:source xml:lang="en-US">Atom Indonesia; Vol 44, No 2 (2018): August 2018; 69-73</dc:source>
	<dc:source>2356-5322</dc:source>
	<dc:source>0126-1568</dc:source>
	<dc:source>10.55981/aij.v44i2</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/view/852/615</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/850</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/851</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/852</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/853</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/990</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/986</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/987</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/988</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/852/989</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2018 Atom Indonesia</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>